dihydroethidium has been researched along with mitoquinone in 1 studies
| Studies (dihydroethidium) | Trials (dihydroethidium) | Recent Studies (post-2010) (dihydroethidium) | Studies (mitoquinone) | Trials (mitoquinone) | Recent Studies (post-2010) (mitoquinone) |
|---|---|---|---|---|---|
| 308 | 3 | 99 | 246 | 5 | 194 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonar, SJ; Dickey, JS; Joseph, J; Kalyanaraman, B; Keller, PW; Klein, SR; Mizuno, N; Rao, VA; Shacter, E; Zielonka, J | 1 |
1 other study(ies) available for dihydroethidium and mitoquinone
| Article | Year |
|---|---|
The antioxidant transcription factor Nrf2 negatively regulates autophagy and growth arrest induced by the anticancer redox agent mitoquinone.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cytotoxins; Fluorescent Dyes; G1 Phase; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; NF-E2-Related Factor 2; Organophosphorus Compounds; Oxidation-Reduction; Oxidative Stress; Phenanthridines; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Ubiquinone | 2010 |